Clinician-Research Scholar (translational science, clinical research, health services research)

I have chosen the "Clinical Scholar" research track. With my prior training in engineering, the completion of a Ph.D.,
and steady research production over the years, I believe this pathway is the best fit for me. While on this track I
have continued a steady stream of publication while maintaining clinical productivity. More recently I have obtained
multiple intramural funding opportunities resulting in preliminary data for a new tracer development. The agent FNP-
59 is radiolabeled cholesterol and has multiple diagnostic applications. This preliminary data has led to a physician
sponsored IND with the FDA and my first R01 application this past June to test in animal cardiovascular models
with a second R01 planned in Feb 2021 to test the agent in humans.

Principal Investigator at the Veterans Administration Ann Arbor Health System (506) for the "Vision" Trial, Phase III
trial to evaluate the efficacy of Lu-PSMA-617

Principle Investigator at University of Michigan for the Phase III "Compete" study. A prospective, randomised,
controlled, open-label, multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide
Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with
inoperable, progressive, somato-statin receptor-positive (SSTR+), Neuroendocrine tumours of gastroenteric or
pancreatic origin (GEP-NET).

Principle Investigator at University of Michigan for the Phase III "Eclipse" study. A multi-center, open-label,
randomized phase 3 trial comparing the safety and efficacy of Lu-PSMA-I&T versus hormone therapy in patients
with metastatic castration-resistant prostate cancer.

Principle Investigator at University of Michigan for the Phase III "SPLASH" study. "SPLASH: Study Evaluating
Metastatic Castrate Resistant Prostate Cancer Treatment Using 17Lu-PNT2002 PSMA Therapy After Second-line
Hormonal Treatment"

Applications of clinical imaging to improve detection and evaluation of treatment response in tumors. Methods to improve and monitor drug delivery

Development of new imaging agents for the detection of human pathology, notably FNP-59 a PET/CT imagable radiolabeled cholesterol